Dr Brad Walsh is Chief Executive Officer and Managing Director of Minomic International Ltd, a Sydney-based commercialisation stage in vitro diagnostic company specialising in cancer detection. He founded Minomic to bring to market an innovative test called MiCheck® Prostate, that gives a risk score for a patient having aggressive prostate cancer. The test has specificity that is twice that of its only competitor meaning the right men go to biopsy.
Dr Walsh has led Minomic’s scientific and business development, raising A$40 million in equity and non-dilutive funding to bring the company to a point at which MiCheck® Prostate has now been launched in the US as an LDT with a marketing team in place to commence the rollout. Additionally, the test has also been launched in Australia. Dr Walsh has also developed a pipeline of potential new diagnostics for bladder and pancreatic cancer. He is co-inventor on 6 patent families and co-author of over 110 peer reviewed papers.